Condition: Waldenström's Macroglobulinemia · Sponsor: BeiGene
The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.
This description comes directly from the study's public registry record.
Study Director · 1-877-828-5568 · clinicaltrials@beigene.com
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Nanfang Hospital, Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| Affiliated Hospital of Hebei University | Baoding, Hebei, China | Recruiting |
| Union Hospital of Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Yichang Central Peoples Hospital | Yichang, Hubei, China | Recruiting |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07169331